ClinicalTrials.gg
CompletedNCT04712903CANTABRICOUpdated Jan 7, 2025Results posted

Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer

A Phase 3 interventional study of Durvalumab and Cisplatin in Small Cell Lung Carcinoma Extensive Disease, sponsored by AstraZeneca. Completed at 34 sites in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-07.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
101
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing durvalumab in Small Cell Lung Carcinoma — 10 open to participants now, 19 under way, 3 of them phase 3. durvalumab · Small Cell Lung Carcinoma.

Enrollment
7th of 36
101 · median 50
Started
2020
with 3 others
Phase 3
6 of 36
none open now
Registered
14th of 36
by date
Lead sponsor
12 of 36
AstraZeneca

Among the 36 studies testing durvalumab in Small Cell Lung Carcinoma, this one is the 7th largest by enrollment, is one of 4 that started in 2020, is one of 6 in phase 3, and was the 14th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

10 of the 36 studies testing durvalumab in Small Cell Lung Carcinoma are open now, in 8 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing durvalumab in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

This is a Phase IIIb, interventional, single arm, multicentre study to evaluate safety, effectivenees, use of resources and patient reporting outcomes in patients with ES-SCLC treated with durvalumab in combination with platinum-etoposide as first-line treatment in Spain.

Read the detailed description

This trial will provide an opportunity to further evaluate the safety profile and efficacy of durvalumab + EP in patient population that is reflective of real-world clinical practice, Durvalumab will be concurrently administered with first-line chemotherapy (EP) on an every 3 week (q3w) schedule for 4 to 6 cycles, and will continue to be administered as monotherapy post-chemotherapy on an every 4 week (q4w) schedule until confirmed progressive disease (PD) or unacceptable toxicity.

Prophylactic cranial irradiation (PCI) is allowed in patients showing complete or partial responses after the durvalumab + EP combination cycles, at the discretion of the investigator according to their local clinical practice.

03

Conditions studied

  • Small Cell Lung Carcinoma Extensive Disease

Keywords

  • Extensive-Stage
  • ICI
  • SCLC
  • Durvalumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically documented Small cell Lung Cancer with extensive disease.
  • Patients who had received chemoradiotherapy for LS-SCLC and have experienced a treatment-free interval of at least 6 months since last chemotherapy, radiotherapy, or chemoradiotherapy cycle, can be included under investigator criteria.
  • ; must be asymptomatic or have been treated at least 2 weeks prior to study treatment and are currently receiving 10 mg/day or less of prednisone or equivalent.
  • Patients must be considered suitable to receive a platinum-based chemotherapy regimen as treatment for ES-SCLC.
  • Performance Status of 0-2 at enrolment.
  • No prior exposure to immune-mediated therapy for cancer.
  • Adequate hematologic and organ function.
  • of at least 12 weeks.
  • Body weight >30 kg.

Exclusion criteria

Exclusion Criteria:

  • Any history of radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy (except paliative care outside of the chest).
  • Paraneoplastic syndrome of nature, requiring systemic treatment or clinical symptomatology suggesting worsening of PNS
  • Active infection including tuberculosis, , anc C
  • Active or prior documented autoimmune or inflammatory disorders
  • Uncontrolled intercurrent illness, including but not limited to interstitial lung disease.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Durvalumab in Combination with Platinum-Etoposide

    Durvalumab 1500 mg via IV infusion will be concurrently administered with first-line chemotherapy (EP) on an every 3 week (q3w) schedule for 4 to 6 cycles, and will continue to be administered post-chemotherapy on an every 4 week (q4w) schedule until confirmed progressive disease (PD) or unacceptable toxicity.

    Drug: Durvalumab · Drug: Cisplatin · Drug: Etoposide · Drug: Carboplatin

Interventions

  • Durvalumab 1500 mg via IV infusion over 60 minutes on Day 1 of each cycle.

  • Cisplatin as an IV infusion per local standards (usually over 60 to 120 minutes on Day 1) of each cycle.

  • Etoposide sequentially administered per local standards (usually over 30 to 60 minutes IV infusion) on Days 1, 2, and 3 of each cycle.

  • Carboplatin as an IV infusion per local standards (usually over 30 to 60 minutes on Day 1) of each cycle.

06

What researchers measure

Primary outcomes

  1. Number of Patients With Adverse Events (AEs) Grade ≥ 3

    Patients with AEs grade ≥ 3 acording to NCI CTCAE v5.0

    Time frame: During study treatment, until disease progression (median 6 months)

  2. Number of Patients With Immune-mediated Adverse Events (imAE)

    Patients with immune-mediated adverse events (imAE) per patient

    Time frame: During study treatment, until disease progression (median 6 months)

Secondary outcomes

  1. Progression Free Survival (PFS).

    PFS: Defined as the time from the first date of treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from investigational product or receives another anticancer therapy prior to progression. Patients who have not progressed or died at the time of analysis will be censored at the time of the latest date of assessment from their last evaluable assessment.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years

  2. Objetive Response Rate (ORR)

    Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) Criteria for target lesions: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

    Time frame: At least every 12 weeks, up to 18 monts

  3. Duration of Response (DoR)

    DoR: Defined as the time from the date of first documented response per RECIST1.1 until the first date of documented progression per RECIST1.1 or death in the absence of disease progression.

    Time frame: From the date of first documented response until the first date of documented progression or death in the absence of disease progression, assessed up to 2 years.

  4. Time to Treatment Discontinuation (TTD)

    TTD: Defined as the time from the first date of treatment until the end of treatment date.

    Time frame: From the first date of treatment until the end of treatment date, assessed up to 2 years.

  5. Overal Survival (OS)

    OS: Defined as the time from the first date of treatment until death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.

    Time frame: From date of inclusion until the date of death, assessed up to 30 months

  6. PFS Rate at 6 Months

    Percentage of participants remaining alive without disease progression at 6 months after initiation of study treatment.

    Time frame: Every 12 weeks

  7. PFS Rate at 12 Months

    Percentage of participants remaining alive without disease progression at 12 months after initiation of study treatment.

    Time frame: Every 12 weeks

  8. DoR Rate at 12 Months

    Percentage of responders remaining alive without disease progression at 12 months after first response.

    Time frame: Every 12 weeks

  9. OS Rate at 6 Months

    Percentage of participants remaining alive at 6 months after initiation of study treatment.

    Time frame: Every 12 weeks

  10. OS Rate at 12 Months

    Percentage of participants remaining alive at 12 months after initiation of study treatment.

    Time frame: Every 12 weeks

  11. OS Rate at 18 Months

    Percentage of participants remaining alive at 18 months after initiation of study treatment.

    Time frame: Every 12 weeks

  12. EORTC QLQ-C30: Global Health Status Domain, Change From Baseline to End of Treatment Visit

    EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For each of these scales, scores range from 0 to 100. For the Global Health Status and the 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  13. EORTC QLQ-C30: Physical Functioning Domain, Change From Baseline to End of Treatment Visit

    EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For each of these scales, scores range from 0 to 100. For the Global Health Status and the 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  14. EORTC QLQ-C30: Role Functioning Domain, Change From Baseline to End of Treatment Visit

    EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For each of these scales, scores range from 0 to 100. For the Global Health Status and the 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  15. EORTC QLQ-C30: Emotional Functioning Domain, Change From Baseline to End of Treatment Visit

    EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For each of these scales, scores range from 0 to 100. For the Global Health Status and the 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  16. EORTC QLQ-C30: Cognitive Functioning Domain, Change From Baseline to End of Treatment Visit

    EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For each of these scales, scores range from 0 to 100. For the Global Health Status and the 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  17. EORTC QLQ-C30: Social Functioning Domain, Change From Baseline to End of Treatment Visit

    EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For each of these scales, scores range from 0 to 100. For the Global Health Status and the 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  18. EORTC QLQ-C30: Fatigue, Change From Baseline to End of Treatment Visit

    EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  19. . EORTC QLQ-C30: Pain, Change From Baseline to End of Treatment Visit

    EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  20. EORTC QLQ-C30: Nausea and Vomiting, Change From Baseline to End of Treatment Visit

    EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  21. EORTC QLQ-C30: Dyspnoea, Change From Baseline to End of Treatment Visit

    EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  22. EORTC QLQ-C30: Insomnia, Change From Baseline to End of Treatment Visit

    EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  23. EORTC QLQ-C30: Appetite Loss, Change From Baseline to End of Treatment Visit

    EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  24. EORCT QLQ-C30: Constipation, Change From Baseline to End of Treatment Visit

    EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  25. EORTC QLQ-C30: Diarrhoea, Change From Baseline to End of Treatment Visit

    EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  26. EORTC QLQ-C30: Financial Difficulties, Change From Baseline to End of Treatment Visit

    EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  27. EORTC QLQ-LC13: Coughing, Change From Baseline to End of Treatment Visit

    EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  28. EORTC QLQ-LC13: Haemoptysis, Change From Baseline to End of Treatment Visit

    EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  29. EORTC QLQ-LC13: Dyspnoea, Change From Baseline to End of Treatment Visit

    EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  30. EORTC QLQ-LC13: Pain in Arm or Shoulder, Change From Baseline to End of Treatment Visit

    EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  31. EORTC QLQ-LC13: Pain in Other Parts, Change From Baseline to End of Treatment Visit

    EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  32. EORTC QLQ-LC13: Sore Mouth, Change From Baseline to End of Treatment Visit

    EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  33. EORTC QLQ-LC13: Peripheral Neuropathy, Change From Baseline to End of Treatment Visit

    EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  34. EORTC QLQ-LC13: Alopecia, Change From Baseline to End of Treatment Visit

    EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  35. EORTC QLQ-LC13: Dysphagia, Change From Baseline to End of Treatment Visit

    EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

  36. EORTC QLQ-LC13: Chest Pain Item Change From Baseline to End of Treatment Visit

    EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

    Time frame: Baseline (cycle 1 day 1) and end of treatment visit.

07

Results

Posted Jan 7, 2025

Participant flow

101 patients were included in the study have been analysed. All patients included in the analysis started treatment with chemotherapy and durvalumab and 81 of them started maintenance treatment with durvalumab.

Participant flow — Overall Study
MilestoneExperimental Arm
Started101
Completed101
Not completed0

Outcome measures

PrimaryNumber of Patients With Adverse Events (AEs) Grade ≥ 3

Patients with AEs grade ≥ 3 acording to NCI CTCAE v5.0

Time frame:
During study treatment, until disease progression (median 6 months)
Reported as:
Count of participants · Participants
Number of Patients With Adverse Events (AEs) Grade ≥ 3
ParticipantsExperimental Arm
Yes77
No24
PrimaryNumber of Patients With Immune-mediated Adverse Events (imAE)

Patients with immune-mediated adverse events (imAE) per patient

Time frame:
During study treatment, until disease progression (median 6 months)
Reported as:
Count of participants · Participants
Number of Patients With Immune-mediated Adverse Events (imAE)
ParticipantsExperimental Arm
Yes38
No63
SecondaryProgression Free Survival (PFS).

PFS: Defined as the time from the first date of treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from investigational product or receives another anticancer therapy prior to progression. Patients who have not progressed or died at the time of analysis will be censored at the time of the latest date of assessment from their last evaluable assessment.

Time frame:
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
Reported as:
Median · Months
Progression Free Survival (PFS).
MonthsExperimental Arm
Progression Free Survival (PFS).6.1 (5.2 to 6.9)
SecondaryObjetive Response Rate (ORR)

Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) Criteria for target lesions: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Time frame:
At least every 12 weeks, up to 18 monts
Reported as:
Number · Percentage of patients
Objetive Response Rate (ORR)
Percentage of patientsExperimental Arm
Objetive Response Rate (ORR)54.5 (44.7 to 64.2)
SecondaryDuration of Response (DoR)

DoR: Defined as the time from the date of first documented response per RECIST1.1 until the first date of documented progression per RECIST1.1 or death in the absence of disease progression.

Time frame:
From the date of first documented response until the first date of documented progression or death in the absence of disease progression, assessed up to 2 years.
Reported as:
Median · Months
Duration of Response (DoR)
MonthsExperimental Arm
Duration of Response (DoR)5.6 (4.7 to 6.5)
SecondaryTime to Treatment Discontinuation (TTD)

TTD: Defined as the time from the first date of treatment until the end of treatment date.

Time frame:
From the first date of treatment until the end of treatment date, assessed up to 2 years.
Reported as:
Median · Months
Time to Treatment Discontinuation (TTD)
MonthsExperimental Arm
Time to Treatment Discontinuation (TTD)6.2 (4.5 to 9.9)
SecondaryOveral Survival (OS)

OS: Defined as the time from the first date of treatment until death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.

Time frame:
From date of inclusion until the date of death, assessed up to 30 months
Reported as:
Median · Months
Overal Survival (OS)
MonthsExperimental Arm
Overal Survival (OS)9.6 (7.8 to 11.3)
SecondaryPFS Rate at 6 Months

Percentage of participants remaining alive without disease progression at 6 months after initiation of study treatment.

Time frame:
Every 12 weeks
Reported as:
Number · Percentage of patients
PFS Rate at 6 Months
Percentage of patientsExperimental Arm
PFS Rate at 6 Months53.0 (43.2 to 62.8)
SecondaryPFS Rate at 12 Months

Percentage of participants remaining alive without disease progression at 12 months after initiation of study treatment.

Time frame:
Every 12 weeks
Reported as:
Number · Percentage of patients
PFS Rate at 12 Months
Percentage of patientsExperimental Arm
PFS Rate at 12 Months21.0 (13.0 to 29.0)
SecondaryDoR Rate at 12 Months

Percentage of responders remaining alive without disease progression at 12 months after first response.

Time frame:
Every 12 weeks
Reported as:
Number · Percentage of patients
DoR Rate at 12 Months
Percentage of patientsExperimental Arm
DoR Rate at 12 Months35.7 (23.0 to 48.4)
SecondaryOS Rate at 6 Months

Percentage of participants remaining alive at 6 months after initiation of study treatment.

Time frame:
Every 12 weeks
Reported as:
Number · Percentage of patients
OS Rate at 6 Months
Percentage of patientsExperimental Arm
OS Rate at 6 Months75.2 (66.8 to 83.6)
SecondaryOS Rate at 12 Months

Percentage of participants remaining alive at 12 months after initiation of study treatment.

Time frame:
Every 12 weeks
Reported as:
Number · Percentage of patients
OS Rate at 12 Months
Percentage of patientsExperimental Arm
OS Rate at 12 Months40.7 (31.1 to 50.3)
SecondaryOS Rate at 18 Months

Percentage of participants remaining alive at 18 months after initiation of study treatment.

Time frame:
Every 12 weeks
Reported as:
Number · Percentage of patients
OS Rate at 18 Months
Percentage of patientsExperimental Arm
OS Rate at 18 Months31.6 (22.4 to 40.8)
SecondaryEORTC QLQ-C30: Global Health Status Domain, Change From Baseline to End of Treatment Visit

EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For each of these scales, scores range from 0 to 100. For the Global Health Status and the 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-C30: Global Health Status Domain, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-C30: Global Health Status Domain, Change From Baseline to End of Treatment Visit-6.3 ± 30.8
SecondaryEORTC QLQ-C30: Physical Functioning Domain, Change From Baseline to End of Treatment Visit

EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For each of these scales, scores range from 0 to 100. For the Global Health Status and the 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-C30: Physical Functioning Domain, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-C30: Physical Functioning Domain, Change From Baseline to End of Treatment Visit-15.0 ± 29.4
SecondaryEORTC QLQ-C30: Role Functioning Domain, Change From Baseline to End of Treatment Visit

EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For each of these scales, scores range from 0 to 100. For the Global Health Status and the 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-C30: Role Functioning Domain, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-C30: Role Functioning Domain, Change From Baseline to End of Treatment Visit-17.0 ± 36.0
SecondaryEORTC QLQ-C30: Emotional Functioning Domain, Change From Baseline to End of Treatment Visit

EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For each of these scales, scores range from 0 to 100. For the Global Health Status and the 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-C30: Emotional Functioning Domain, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-C30: Emotional Functioning Domain, Change From Baseline to End of Treatment Visit-2.3 ± 30.4
SecondaryEORTC QLQ-C30: Cognitive Functioning Domain, Change From Baseline to End of Treatment Visit

EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For each of these scales, scores range from 0 to 100. For the Global Health Status and the 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-C30: Cognitive Functioning Domain, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-C30: Cognitive Functioning Domain, Change From Baseline to End of Treatment Visit-15.0 ± 24.0
SecondaryEORTC QLQ-C30: Social Functioning Domain, Change From Baseline to End of Treatment Visit

EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For each of these scales, scores range from 0 to 100. For the Global Health Status and the 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-C30: Social Functioning Domain, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-C30: Social Functioning Domain, Change From Baseline to End of Treatment Visit-12.0 ± 31.0
SecondaryEORTC QLQ-C30: Fatigue, Change From Baseline to End of Treatment Visit

EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-C30: Fatigue, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-C30: Fatigue, Change From Baseline to End of Treatment Visit12.4 ± 29.4
Secondary. EORTC QLQ-C30: Pain, Change From Baseline to End of Treatment Visit

EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
. EORTC QLQ-C30: Pain, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
. EORTC QLQ-C30: Pain, Change From Baseline to End of Treatment Visit0.2 ± 29.2
SecondaryEORTC QLQ-C30: Nausea and Vomiting, Change From Baseline to End of Treatment Visit

EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-C30: Nausea and Vomiting, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-C30: Nausea and Vomiting, Change From Baseline to End of Treatment Visit0.7 ± 20.1
SecondaryEORTC QLQ-C30: Dyspnoea, Change From Baseline to End of Treatment Visit

EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-C30: Dyspnoea, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-C30: Dyspnoea, Change From Baseline to End of Treatment Visit-2.4 ± 37.2
SecondaryEORTC QLQ-C30: Insomnia, Change From Baseline to End of Treatment Visit

EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-C30: Insomnia, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-C30: Insomnia, Change From Baseline to End of Treatment Visit1.0 ± 36.4
SecondaryEORTC QLQ-C30: Appetite Loss, Change From Baseline to End of Treatment Visit

EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-C30: Appetite Loss, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-C30: Appetite Loss, Change From Baseline to End of Treatment Visit-2.4 ± 36.3
SecondaryEORCT QLQ-C30: Constipation, Change From Baseline to End of Treatment Visit

EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORCT QLQ-C30: Constipation, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORCT QLQ-C30: Constipation, Change From Baseline to End of Treatment Visit6.3 ± 33.5
SecondaryEORTC QLQ-C30: Diarrhoea, Change From Baseline to End of Treatment Visit

EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-C30: Diarrhoea, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-C30: Diarrhoea, Change From Baseline to End of Treatment Visit0.0 ± 18.1
SecondaryEORTC QLQ-C30: Financial Difficulties, Change From Baseline to End of Treatment Visit

EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties). For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-C30: Financial Difficulties, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-C30: Financial Difficulties, Change From Baseline to End of Treatment Visit10.3 ± 22.0
SecondaryEORTC QLQ-LC13: Coughing, Change From Baseline to End of Treatment Visit

EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-LC13: Coughing, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-LC13: Coughing, Change From Baseline to End of Treatment Visit-7.8 ± 29.7
SecondaryEORTC QLQ-LC13: Haemoptysis, Change From Baseline to End of Treatment Visit

EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-LC13: Haemoptysis, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-LC13: Haemoptysis, Change From Baseline to End of Treatment Visit-0.5 ± 15.2
SecondaryEORTC QLQ-LC13: Dyspnoea, Change From Baseline to End of Treatment Visit

EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-LC13: Dyspnoea, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-LC13: Dyspnoea, Change From Baseline to End of Treatment Visit3.1 ± 24.1
SecondaryEORTC QLQ-LC13: Pain in Arm or Shoulder, Change From Baseline to End of Treatment Visit

EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-LC13: Pain in Arm or Shoulder, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-LC13: Pain in Arm or Shoulder, Change From Baseline to End of Treatment Visit3.3 ± 33.4
SecondaryEORTC QLQ-LC13: Pain in Other Parts, Change From Baseline to End of Treatment Visit

EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-LC13: Pain in Other Parts, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-LC13: Pain in Other Parts, Change From Baseline to End of Treatment Visit7.4 ± 39.4
SecondaryEORTC QLQ-LC13: Sore Mouth, Change From Baseline to End of Treatment Visit

EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-LC13: Sore Mouth, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-LC13: Sore Mouth, Change From Baseline to End of Treatment Visit2.3 ± 13.0
SecondaryEORTC QLQ-LC13: Peripheral Neuropathy, Change From Baseline to End of Treatment Visit

EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-LC13: Peripheral Neuropathy, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-LC13: Peripheral Neuropathy, Change From Baseline to End of Treatment Visit13.6 ± 27.4
SecondaryEORTC QLQ-LC13: Alopecia, Change From Baseline to End of Treatment Visit

EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-LC13: Alopecia, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-LC13: Alopecia, Change From Baseline to End of Treatment Visit18.1 ± 37.5
SecondaryEORTC QLQ-LC13: Dysphagia, Change From Baseline to End of Treatment Visit

EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-LC13: Dysphagia, Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-LC13: Dysphagia, Change From Baseline to End of Treatment Visit2.8 ± 23.6
SecondaryEORTC QLQ-LC13: Chest Pain Item Change From Baseline to End of Treatment Visit

EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication. Scores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. Change from baseline is the difference in the score between the end of treatment visit and the first visit.

Time frame:
Baseline (cycle 1 day 1) and end of treatment visit.
Reported as:
Mean · Units on a scale
EORTC QLQ-LC13: Chest Pain Item Change From Baseline to End of Treatment Visit
Units on a scaleCompleted
EORTC QLQ-LC13: Chest Pain Item Change From Baseline to End of Treatment Visit-1.8 ± 29.3

Adverse events

Collected over During study treatment, until disease progression (median 6 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental Arm76/101 (75.2%)57/101 (56.4%)100/101 (99%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventExperimental Arm
Febrile neutropeniaBlood and lymphatic system disorders8/101
PneumoniaInfections and infestations6/101
PyrexiaGeneral disorders5/101
SepsisInfections and infestations4/101
DyspnoeaRespiratory, thoracic and mediastinal disorders4/101
HyponatraemiaMetabolism and nutrition disorders3/101
PneumonitisRespiratory, thoracic and mediastinal disorders3/101
NeutropeniaBlood and lymphatic system disorders2/101
PancytopeniaBlood and lymphatic system disorders2/101
Inappropriate antidiuretic hormone secretionEndocrine disorders2/101
Most frequent other events
Showing 10 of 43
Most frequent other events
EventExperimental Arm
AstheniaGeneral disorders64/101
AnaemiaBlood and lymphatic system disorders50/101
NeutropeniaBlood and lymphatic system disorders34/101
DyspnoeaRespiratory, thoracic and mediastinal disorders31/101
ConstipationGastrointestinal disorders27/101
AlopeciaSkin and subcutaneous tissue disorders24/101
CoughRespiratory, thoracic and mediastinal disorders23/101
DiarrhoeaGastrointestinal disorders21/101
ThrombocytopeniaBlood and lymphatic system disorders19/101
NauseaGastrointestinal disorders18/101

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Experimental Arm
<=18 years0
Between 18 and 65 years44
>=65 years57
Age, Continuous
Age, Continuous(Years)Experimental Arm
Mean66.2 ± 7.2
Sex: Female, Male
Sex: Female, Male(Participants)Experimental Arm
Female33
Male68
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental Arm
Hispanic or Latino21
Not Hispanic or Latino80
Unknown or Not Reported0
Weight
Weight(Kg)Experimental Arm
Mean75.6 ± 16.8
Smoking status
Smoking status(Participants)Experimental Arm
Current smoker46
Former smoker53
Not available2
08

Study locations

34 sites
  • Research Site
    A Coruna, 15006, Spain
  • Research Site
    Alicante, 03010, Spain
  • Research Site
    Badajoz, 6006, Spain
  • Research Site
    Badalona, 08916, Spain
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Barcelona, 08908, Spain
  • Research Site
    Barcelona, 8003, Spain
  • Research Site
    Barcelona, ?08041, Spain
  • Research Site
    Castellon de la Plana, 12004, Spain
  • Research Site
    Córdoba, 14004, Spain
  • Research Site
    Galdakao, 48960, Spain
  • Research Site
    Granada, 18014, Spain
  • Research Site
    Jaén, 23007, Spain
  • Research Site
    La Laguna, 38320, Spain
  • Research Site
    León, 24071, Spain
  • Research Site
    Madrid, 28027, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Majadahonda, 28222, Spain
  • Research Site
    Mataro, 08304, Spain
  • Research Site
    Murcia, 30008, Spain
  • Research Site
    Málaga, 29011, Spain
  • Research Site
    Ourense, 32005, Spain
  • Research Site
    Oviedo, 33011, Spain
  • Research Site
    Palma, 07198, Spain
  • Research Site
    Reus,Tarragona, 43204, Spain
  • Research Site
    San Sebastián, 20014, Spain
  • Research Site
    Santander, 39008, Spain
  • Research Site
    Santiago de Compostela, 15706, Spain
  • Research Site
    Toledo, 45004, Spain
  • Research Site
    Valencia, 46026, Spain
  • Research Site
    Valladolid, 47003, Spain
  • Research Site
    Zaragoza, 50009, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jun 2023, 30 months.

Results were first posted in Jan 2025, 1 year 6 months after primary completion.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's 30 months is below that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2020
First posted
Jan 15, 2021
StartActual
Dec 16, 2020
Primary completionActual
Jun 21, 2023
CompletionActual
Jun 21, 2023
Results first posted
Jan 7, 2025
Last update
Jan 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04712903
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 15, 2021
Start date
Dec 16, 2020
Primary completion
Jun 21, 2023
Completion
Jun 21, 2023
Results posted
Jan 7, 2025
Last update
Jan 7, 2025

Study contacts

Dolores Isla, M.D.
principal investigator · Hospital Clínico Lozano Blesa, Zaragoza

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Etoposide

Start the discussion